Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rentokil chief Andy Ransom to retire

(Sharecast News) - Rentokil Initial announced on Wednesday that its chief executive officer Andy Ransom would retire by the time of its annual general meeting in 2026, bringing to a close a 17-year tenure on the board, including 12 years as CEO. The FTSE 100 pest control and hygiene specialist said the search for his successor was already underway, led by chair Richard Solomons.

It credited Ransom with transforming Rentokil Initial into a global leader in pest control, with the board saying the group was well positioned for long-term growth, supported by strong structural drivers in the industry.

Solomons noted that while long-term prospects remained compelling, its management was focussed in the near term on turning around the company's underperforming North American business.

Ransom said it had been a privilege to lead the group, adding that he would remain focused on delivering growth in North America and other core markets ahead of a smooth leadership transition.

Rentokil said he would be treated as a good leaver for the purposes of incentive schemes, in line with the company's remuneration policy.

At 1133 BST, shares in Rentokil Initial were down 1.55% at 355.91p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.